Oragenics, Inc. (OGEN)

NYSEAMERICAN: OGEN · IEX Real-Time Price · USD
7.14
+0.35 (5.12%)
Feb 3, 2023, 4:00 PM EST - Market closed
5.12%
Market Cap 14.00M
Revenue (ttm) 218,508
Net Income (ttm) -16.28M
Shares Out 1.96M
EPS (ttm) -7.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 57,664
Open 6.65
Previous Close 6.79
Day's Range 6.65 - 7.25
52-Week Range 6.00 - 26.40
Beta 0.39
Analysts Buy
Price Target 1.53 (-78.56%)
Earnings Date Mar 23, 2023

About OGEN

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to pre... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 5
Stock Exchange NYSEAMERICAN
Ticker Symbol OGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for OGEN stock is "Buy." The 12-month stock price forecast is $1.53, which is a decrease of -78.56% from the latest price.

Price Target
$1.53
(-78.56% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Oragenics, Inc. Regains Compliance with NYSE American

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced th...

2 days ago - Business Wire

7 Short-Squeeze Stocks to Buy Before They Soar

As much as we may recognize that short sellers perform a valuable service for the equities market, the concept of targeting short-squeeze stocks to buy just to penalize the pessimists carries catharti...

Other symbols: CETXSIENSKINSTRWRBYYOU
6 days ago - InvestorPlace

Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced th...

1 month ago - Business Wire

Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, today announ...

1 month ago - Business Wire

Oragenics, Inc. Receives NYSE American Notice

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced th...

1 month ago - Business Wire

Oragenics, Inc. Announces New Chair

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced th...

1 month ago - Business Wire

Oragenics Issues Letter to Shareholders

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronaviruses, today issued th...

4 months ago - Business Wire

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

5 months ago - Business Wire

Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

8 months ago - Business Wire

Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports

8 months ago - Business Wire

Oragenics to Participate at the World Vaccine Congress Washington 2022

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics to Participate at the World Vaccine Congress Washington 2022

10 months ago - Business Wire

Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses

10 months ago - Business Wire

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

11 months ago - Business Wire

Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

11 months ago - Business Wire

Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1

11 months ago - Business Wire

Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Positive Data on their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

1 year ago - Business Wire

Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

1 year ago - Business Wire

5 Stocks Insiders Are Buying Right Now

Several stocks that insiders are buying are worth watching as we enter the new year. This week, that list includes F, CRCT, CHWY and OGEN.

Other symbols: ASANCHWYCRCTF
1 year ago - InvestorPlace

OGEN Stock Alert: The Insider Buying Giving Oragenics Shares Some Oomph Today

Oragenics (OGEN) stock is rising higher on Tuesday following news of massive insider buying at the development-stage company. The post OGEN Stock Alert: The Insider Buying Giving Oragenics Shares Some...

1 year ago - InvestorPlace

Oragenics Extends Collaboration with NRC Canada For Omicron-Specific Vaccine

Oragenics Inc (NYSE: OGEN) has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) to enable Oragenics to pursue an intranasal vaccine designed against ...

1 year ago - Benzinga

Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant

1 year ago - Business Wire

Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners

1 year ago - Business Wire

Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics

1 year ago - Business Wire

Oragenics COVID-19 Vaccine Candidate Shows Encouraging Preclinical Action

Oragenics Inc (NYSE: OGEN) announced the results from its hamster challenge study to evaluate the COVID-19 vaccine candidate. The study is assessing the immunogenicity and viral load reduction impact ...

1 year ago - Benzinga